The impact of pioglitazone on bladder cancer and cardiovascular events

Consultant Pharmacist

Volumn 29, Issue 8, 2014, Pages 555-558

  Lee, Esther J ^a   Marcy, Todd R ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

Bladder cancer; Cardiovascular toxicity; Pioglitazone; Rosiglitazone; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

PIOGLITAZONE; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; DRUG THERAPY; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT DECISION MAKING; BLADDER TUMOR; HEART INFARCTION; RISK;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; PIOGLITAZONE; RISK; URINARY BLADDER NEOPLASMS;

EID: 84928315452     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2014.555     Document Type: Article

References (11)

1. CDC. National Diabetes Fact Sheet 2011. Available at http://www.cdc.gov/diabetes/pubs/factsheetll.htm. Accessed September 30, 2013.
2. Actos (pioglitazone) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; August 2012.
3. Colmers IN, Bowker SL, Majumdar SR et al. Use of thiazo-lidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184:E675-83.
4. Zhu Z, Shen Z, Lu Y et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012; 98:159-63.
5. Mamtani R, Haynes K, Bilker WB et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012; 104:1411-21.
6. Lewis JD, Ferrara A, Peng T et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34:916-22.
7. Oliveria SA, Koro CE, Yood U. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndrome Clin Res Rev 2008; 2:47-57.
8. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71.
9. Lincoff AM, Wolski K, Nicholls SJ et al. Pioglitazone and risk of CV events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-8.
10. Avandia (rosiglitazone) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; September 2013.
11. FDA Drug Safety Communication. Update to Ongoing Safety Review of Actos (Pioglitazone) and Increased Risk of Bladder Cancer. Available at http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed September 30, 2013.